INSM
Price
$196.74
Change
+$1.50 (+0.77%)
Updated
Dec 12, 04:31 PM (EDT)
Capitalization
41.64B
69 days until earnings call
Intraday BUY SELL Signals
KRYS
Price
$247.61
Change
+$0.84 (+0.34%)
Updated
Dec 12, 11:43 AM (EDT)
Capitalization
7.16B
80 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

INSM vs KRYS

Header iconINSM vs KRYS Comparison
Open Charts INSM vs KRYSBanner chart's image
Insmed
Price$196.74
Change+$1.50 (+0.77%)
Volume$3K
Capitalization41.64B
Krystal Biotech
Price$247.61
Change+$0.84 (+0.34%)
Volume$200
Capitalization7.16B
INSM vs KRYS Comparison Chart in %
View a ticker or compare two or three
VS
INSM vs. KRYS commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a StrongBuy and KRYS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (INSM: $195.24 vs. KRYS: $246.77)
Brand notoriety: INSM and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INSM: 95% vs. KRYS: 86%
Market capitalization -- INSM: $41.64B vs. KRYS: $7.16B
INSM [@Biotechnology] is valued at $41.64B. KRYS’s [@Biotechnology] market capitalization is $7.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $113.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INSM’s FA Score shows that 1 FA rating(s) are green whileKRYS’s FA Score has 1 green FA rating(s).

  • INSM’s FA Score: 1 green, 4 red.
  • KRYS’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than INSM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INSM’s TA Score shows that 4 TA indicator(s) are bullish while KRYS’s TA Score has 3 bullish TA indicator(s).

  • INSM’s TA Score: 4 bullish, 4 bearish.
  • KRYS’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, INSM is a better buy in the short-term than KRYS.

Price Growth

INSM (@Biotechnology) experienced а -4.78% price change this week, while KRYS (@Biotechnology) price change was +11.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.68%. For the same industry, the average monthly price growth was +4.10%, and the average quarterly price growth was +64.61%.

Reported Earning Dates

INSM is expected to report earnings on Feb 19, 2026.

KRYS is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (+0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($41.6B) has a higher market cap than KRYS($7.16B). INSM YTD gains are higher at: 182.793 vs. KRYS (57.523). KRYS has higher annual earnings (EBITDA): 158M vs. INSM (-938.1M). INSM has more cash in the bank: 1.86B vs. KRYS (682M). KRYS has less debt than INSM: KRYS (9.68M) vs INSM (576M). INSM has higher revenues than KRYS: INSM (398M) vs KRYS (359M).
INSMKRYSINSM / KRYS
Capitalization41.6B7.16B581%
EBITDA-938.1M158M-594%
Gain YTD182.79357.523318%
P/E RatioN/A37.00-
Revenue398M359M111%
Total Cash1.86B682M272%
Total Debt576M9.68M5,950%
FUNDAMENTALS RATINGS
INSM vs KRYS: Fundamental Ratings
INSM
KRYS
OUTLOOK RATING
1..100
7831
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
318
SMR RATING
1..100
9953
PRICE GROWTH RATING
1..100
3737
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INSM's Valuation (79) in the Biotechnology industry is in the same range as KRYS (80) in the Pharmaceuticals Major industry. This means that INSM’s stock grew similarly to KRYS’s over the last 12 months.

INSM's Profit vs Risk Rating (3) in the Biotechnology industry is in the same range as KRYS (18) in the Pharmaceuticals Major industry. This means that INSM’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's SMR Rating (53) in the Pharmaceuticals Major industry is somewhat better than the same rating for INSM (99) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than INSM’s over the last 12 months.

KRYS's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as INSM (37) in the Biotechnology industry. This means that KRYS’s stock grew similarly to INSM’s over the last 12 months.

KRYS's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as INSM (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to INSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INSMKRYS
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
70%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 18 days ago
70%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 24 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
INSM
Daily Signal:
Gain/Loss:
KRYS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SMLL21.030.15
+0.74%
Harbor Active Small Cap ETF
CHW7.440.03
+0.47%
Calamos Global Dynamic Income Fund
DSI129.660.08
+0.06%
iShares ESG MSCI KLD 400 ETF
PHD9.95N/A
N/A
Pioneer Floating Rate Fund
PJFM58.85N/A
N/A
PGIM Jennison Focused Mid-Cap ETF

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with VRDN. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then VRDN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+2.94%
VRDN - KRYS
47%
Loosely correlated
-0.09%
CGON - KRYS
47%
Loosely correlated
-0.31%
XNCR - KRYS
47%
Loosely correlated
-0.58%
IDYA - KRYS
47%
Loosely correlated
-0.24%
NUVL - KRYS
46%
Loosely correlated
+0.16%
More